Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05272696

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

Induction Therapy With Nab-paclitaxel, Cisplatin and Pembrolizumab in Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma

Sponsor: Guangdong Provincial People's Hospital

Conditions Head and Neck Squamous Cell Carcinoma

Interventions Adjuvant Chemoradiotherapy Nab-paclitaxel, cisplatin and Pembrolizumab combination Radical concurrent chemoradiotherapy surgery

Updated 6 times since 2022 Last updated: Jun 30, 2025 Started: Mar 1, 2022 Primary completion: Jan 1, 2026 Completion: Jan 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Head and Neck Squamous Cell Carcinoma, this trial is actively recruiting participants. The trial is conducted by Guangdong Provincial People's Hospital and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Aug 2025 — Present [monthly]

Recruiting PHASE2

Status: Unknown → Recruiting
Mar 2025 — Aug 2025 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Apr 2022 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong Provincial People's Hospital

Data source: Guangdong Provincial People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China